C

Clinical Endpoints | Scottsdale, AZ

Research site

(Unclaimed)

Location

9977 North 95th Street, Suite 101, Scottsdale, Arizona, United States of America

Site insights

Top conditions

Top treatments

CY6463

Frexalimab

BOTOX

ACU193

SAR441344

Simufilam

NE3107

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 6 total trials

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral do...

Enrolling

Multiple Sclerosis

Drug: Activated charcoal

Drug: Cholestyramine

Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease (REFOCUS-ALZ)

A 76-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 76 we...

Active, not recruiting

Alzheimer Disease

Drug: Placebo

Drug: Simufilam

Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine

Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and so...

Active, not recruiting

Episodic Migraine

Drug: Placebo

Drug: BOTOX